The Ambidextrous Medical Device Industry
Executive SummaryWith the public markets for now all but closed to them, small, private medical device firms are forced to turn to a number of new financing and business models. There will be no public-market support unless the companies can live up to sales and earnings projections. The historic split between small companies as innovators and big companies as disseminators of new technology has shifted slightly in the wake of the new financing environment, resulting in an imbalance favoring big companies.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.